Abstract Number: 1848 • ACR Convergence 2023
Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease
Background/Purpose: The HPV vaccine is safe and immunogenic in RD patients but uptake is suboptimal. We aimed to evaluate factors associated with HPV vaccination in…Abstract Number: 0219 • ACR Convergence 2023
Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab
Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…Abstract Number: 1856 • ACR Convergence 2023
Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project
Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…Abstract Number: 0616 • ACR Convergence 2023
Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study
Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…Abstract Number: 1895 • ACR Convergence 2023
Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies
Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…Abstract Number: 0742 • ACR Convergence 2023
Risk of Incident Gout Associated with Initiation of Sodium-glucose cotransporter-2 Inhibitors versus Other Second-line Agents Among Metformin Users with Type 2 Diabetes
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are a revolutionary second-line treatment for type 2 diabetes associated with lower risk of cardiovascular and all-cause mortality, heart failure,…Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…Abstract Number: 0751 • ACR Convergence 2023
Recombinant Zoster Vaccination Among U.S. Veterans Receiving Immunosuppressive Medications 2017-2023
Background/Purpose: Patients receiving immunosuppressive therapies are known to have a higher risk of herpes zoster and subsequent complications compared to the general population. The recombinant…Abstract Number: 2027 • ACR Convergence 2023
Developing and Implementing a Pilot Educational Intervention to Improve Readiness for Self-Management Among Patients with Rheumatic Diseases in Uganda
Background/Purpose: Self-management is an effective strategy for improving health outcomes among patients with chronic conditions such as rheumatic diseases. Patient education about self-management among patients…Abstract Number: 0811 • ACR Convergence 2023
Comparative Effectiveness of Sodium-glucose cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-primary Emergency Department Visits and Hospitalizations: A General Population Cohort Study
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) lower serum urate (primary prevention); however, whether this translates into preventing recurrent flares among gout patients (secondary prevention) and gout-primary…Abstract Number: 2038 • ACR Convergence 2023
Impact of COVID-19 Pandemic on Preventative Health Screenings in Rheumatology Outpatients
Background/Purpose: The COVID-19 pandemic created significant barriers to accessing recommended preventative health screening. Patients already managing a chronic disease, particularly those using immunosuppressive medications, may…Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…Abstract Number: 2055 • ACR Convergence 2023
A Randomized Controlled Trial of Two Hepatitis a Vaccine Doses Among Adolescents with Juvenile Idiopathic Arthritis and Crohn’s Disease on Immunosuppressive Therapy: A Pilot Study
Background/Purpose: Juvenile idiopathic arthritis (JIA) and Crohn's disease (CD) are now controlled using immunosuppressive medications. However, disease control comes at the risk of increased infection.…Abstract Number: 0858 • ACR Convergence 2023
Randomized, Controlled, Double-Blind Trial on the Impact of Rosuvastatin on Sublinical Markers of Atherosclerosis in Patients with ANCA-Associated Vasculitis
Background/Purpose: Despite more effective therapeutic strategies in ANCA-associated vasculitis (AAV), there is still a significant risk of morbidity and mortality, mainly due to infection, and…Abstract Number: 2132 • ACR Convergence 2023
Systematic Screening for Multimorbidities Leads to an Increased Use of Comorbidity-preventing Medications and Lower Hospitalization Rates
Background/Purpose: Systematic screening for multimorbidities has been carried out since 2014 at Montpellier University Hospital in patients with chronic inflammatory rheumatism (IRD). The aim of…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »